mordor-ab-treatment-public-codebook.txt Updated December 2, 2021 This dataset includes treatment status for children ages 1-59 months in 30 communities in rural Niger that were enrolled in a randomized controlled trial to study the effects of biannual mass azithromycin distribution on antimicrobial resistance and pathogen infection. Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02048007 Key publications that reported separate outcomes from these same 30 communities are: Arzika, A. M., Maliki, R., Boubacar, N., Kane, S., Cotter, S. Y., Lebas, E., Cook, C., Bailey, R. L., West, S. K., Rosenthal, P. J., Porco, T. C., Lietman, T. M., Keenan, J. D. & MORDOR Study Group. Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trial. PLoS Med. 16, e1002835 (2019). https://pubmed.ncbi.nlm.nih.gov/31237871/ Doan, T., Hinterwirth, A., Worden, L., Arzika, A. M., Maliki, R., Abdou, A., Kane, S., Zhong, L., Cummings, S. L., Sakar, S., Chen, C., Cook, C., Lebas, E., Chow, E. D., Nachamkin, I., Porco, T. C., Keenan, J. D. & Lietman, T. M. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat. Med. 25, 1370–1376 (2019). https://pubmed.ncbi.nlm.nih.gov/31406349/ The dataset includes 30,792 observations and 8 variables The data include 30 clusters (clusterid_public) and 9,066 unique children (childid_public). IMPORTANT: there are additional children that appear in this dataset compared with the antibody analysis dataset (mordor-ab-analysis-public.csv/.rds). These additional children were not enrolled in the dried blood spot specimen collection substudy. They were enrolled in the overall trial and may have contributed to other parts of the study. They are relevant for estimating treatment coverage in the clusters over the course of the trial, using the indicator in this dataset (treated) The data are in long format, with a single observation corresponding to a child-phase. The study visited clusters at 6-month intervals (0,6,12,...36). The variable "phase" indexes the study visit. Treatment dates (trdate) are in date format but have been set to the 15th of each month, and are accurate to YYYY-MM. The format is thus YYYY-MM-15. We masked the day to comply with guidance from our IRB and Dryad on protecting participant confidentiality. These data are used to estimate treatment coverage by study phase. Unlike the antibody data in mordor-ab-analysis-public.csv/.rds, treatment was measured at every visit in 6-month intervals. Antibody data are in 12 month intervals with an extra visit at phase = 6 months. Variable descriptions $ clusterid_public: cluster ID for the community $ arm : cluster-level intervention assignment (placebo, azithro) $ phase : study visit in months since baseline (0 = baseline, 6, 12,.., 36) $ childid_public : child ID $ agem : child age in months $ female : child sex assigned at birth is female (female = 1, male = 0) $ trdate : treatment date (azithromycin or placebo distribution at the community level) $ treated : binary indicator of whether the child was treated with azithromycin or placebo, depending on arm > str(d) tibble [30,792 × 8] (S3: tbl_df/tbl/data.frame) $ clusterid_public: chr [1:30792] "community-13" "community-13" "community-4" "community-9" ... $ arm : Factor w/ 2 levels "placebo","azithro": 1 1 1 2 1 1 1 2 2 2 ... $ phase : num [1:30792] 30 36 24 24 24 30 36 24 24 30 ... $ childid_public : chr [1:30792] "child-4732" "child-4732" NA NA ... $ agem : num [1:30792] 10.85 13.87 34.36 8.05 1.41 ... $ female : num [1:30792] 0 0 1 0 1 1 1 0 0 0 ... $ trdate : Date[1:30792], format: "2018-02-15" "2018-05-15" ... $ treated : num [1:30792] 1 1 1 1 1 1 1 1 1 1 ...